NCT02158858 2025-10-08
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Phase 1/2 Completed
Clinical Trials
11 trialsNCT03878199 2025-09-15
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT03144687 2022-06-16
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
Incyte Corporation
Phase 2 Completed
NCT02038036 2021-07-20
RESPONSE-2
Novartis
Phase 3 Completed
NCT01787552 2020-04-15
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Novartis
Phase 1/2 Completed
NCT01348490 2020-01-28
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
Incyte Corporation
Phase 2 Completed
NCT02292446 2019-07-18
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
Novartis
Phase 3 Completed
NCT02076191 2019-02-28
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT00952289 2018-03-12
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Incyte Corporation
Phase 3 Completed
NCT01164163 2014-10-23
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Children's Oncology Group
Phase 1 Completed
NCT01340651 2014-03-10
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Incyte Corporation
Phase 2 Completed